Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.

Linker RA, Gold R.

Curr Neurol Neurosci Rep. 2013 Nov;13(11):394. doi: 10.1007/s11910-013-0394-8. Review.

PMID:
24061646
2.

Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.

Burness CB, Deeks ED.

CNS Drugs. 2014 Apr;28(4):373-87. doi: 10.1007/s40263-014-0155-5. Review.

PMID:
24623127
3.

Dimethyl fumarate for multiple sclerosis.

Xu Z, Zhang F, Sun F, Gu K, Dong S, He D.

Cochrane Database Syst Rev. 2015 Apr 22;(4):CD011076. doi: 10.1002/14651858.CD011076.pub2. Review.

PMID:
25900414
4.

Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.

Venci JV, Gandhi MA.

Ann Pharmacother. 2013 Dec;47(12):1697-702. doi: 10.1177/1060028013509232. Epub 2013 Oct 23. Review. Erratum in: Ann Pharmacother. 2014 May;48(5):668. Dosage error in article text.

PMID:
24259625
5.

Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.

Stangel M, Linker RA.

Expert Rev Clin Pharmacol. 2013 Jul;6(4):355-62. doi: 10.1586/17512433.2013.811826. Review.

PMID:
23927662
6.

[Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].

Matolcsi J, Rózsa C.

Ideggyogy Sz. 2015 Jan 30;68(1-2):7-14. Review. Hungarian.

PMID:
25842911
7.

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators.

Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Erratum in: Lancet. 2009 Apr 18;373(9672):1340.

PMID:
18970976
8.

Dimethyl Fumarate: A Review in Relapsing-Remitting MS.

Deeks ED.

Drugs. 2016 Feb;76(2):243-54. doi: 10.1007/s40265-015-0528-1. Review.

PMID:
26689201
9.

Dimethyl fumarate for treating relapsing multiple sclerosis.

Sheremata W, Brown AD, Rammohan KW.

Expert Opin Drug Saf. 2015 Jan;14(1):161-70. doi: 10.1517/14740338.2015.977251. Epub 2014 Nov 8. Review.

PMID:
25382392
10.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N Engl J Med. 2012 Dec 13;367(24):2362.

11.

Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.

Methner A, Zipp F.

Nat Rev Neurol. 2013 Feb;9(2):72-3. doi: 10.1038/nrneurol.2012.277. Epub 2013 Jan 22. Review. Erratum in: Nat Rev Neurol. 2013 May;9(5):240.

PMID:
23338282
12.

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.

Nicholas JA, Boster AL, Imitola J, O'Connell C, Racke MK.

Drug Des Devel Ther. 2014 Jul 7;8:897-908. doi: 10.2147/DDDT.S50962. eCollection 2014. Review.

13.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
14.

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.

Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT.

Curr Med Res Opin. 2014 Feb;30(2):251-62. doi: 10.1185/03007995.2013.849236. Epub 2013 Oct 22. Review.

PMID:
24131282
15.

Dimethyl fumarate for multiple sclerosis.

Papadopoulou A, D'Souza M, Kappos L, Yaldizli O.

Expert Opin Investig Drugs. 2010 Dec;19(12):1603-12. doi: 10.1517/13543784.2010.534778. Epub 2010 Nov 11. Review.

PMID:
21067468
16.

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).

Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NC.

Mult Scler. 2015 Jan;21(1):57-66. doi: 10.1177/1352458514537013. Epub 2014 Jul 2.

17.

BG-12 in multiple sclerosis.

Phillips JT, Fox RJ.

Semin Neurol. 2013 Feb;33(1):56-65. doi: 10.1055/s-0033-1343796. Epub 2013 May 25. Review.

PMID:
23709213
18.

Dimethyl fumarate : a Janus-faced substance?

Kees F.

Expert Opin Pharmacother. 2013 Aug;14(11):1559-67. doi: 10.1517/14656566.2013.804912. Epub 2013 May 22. Review.

PMID:
23697607
19.

Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS.

Limmroth V.

Nat Rev Neurol. 2013 Jan;9(1):8-10. doi: 10.1038/nrneurol.2012.231. Epub 2012 Nov 13. No abstract available.

PMID:
23147843
20.

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.

Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT.

Mult Scler. 2014 Feb;20(2):243-52. doi: 10.1177/1352458513507817. Epub 2013 Oct 22.

PMID:
24150779

Supplemental Content

Support Center